Two recently concluded clinical trials and other phase I trials are now recruiting refractory CLL patients who will be infused with anti-CD19/CD20 bispecific CAR T cells ([124]; NCT04260945, NCT04156178, NCT03398967). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.